title: Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial.
abstract: The safety, pharmacokinetics, and pharmacodynamics of single oral doses of up to 48 mg and daily (for 28 days) doses of up 24 mg mofegiline were investigated in healthy male volunteers. Plasma pharmacokinetics indicated rapid absorption and elimination: time to reach maximum concentration occurred at about 1 hour; half-life ranged from 1 to 3 hours. Maximal plasma concentration and area under the plasma concentration-time curve increased and oral clearance decreased disproportionately with dose. Mofegiline rapidly and markedly inhibited platelet monoamine oxidase B (MAOB) activity, which returned to baseline within 14 days. Urinary excretion of phenylethylamine increased proportionately with doses up to 24 mg. No changes in urinary elimination of catecholamines, blood pressure, heart rate, or ECG were observed. A classic maximum tolerated dose was not achieved in these studies. However, the 48 mg single dose and the 24 mg multiple daily dose far exceeded the dose (1 mg) that was associated with > 90% platelet MAOB inhibition.
authors.affiliation: Marion Merrell Dow, Inc., Kansas City, MO 64134, USA.
authors.forename: M
authors.initials: M
authors.lastname: Stoltz
authors.forename: D
authors.initials: D
authors.lastname: Reynolds
authors.forename: L
authors.initials: L
authors.lastname: Elkins
authors.forename: D
authors.initials: D
authors.lastname: Salazar
authors.forename: S
authors.initials: S
authors.lastname: Weir
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000498:Allyl Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D002082:Butylamines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D016037:Single-Blind Method
chemical_list: D000498:Allyl Compounds; D000978:Antiparkinson Agents; D002082:Butylamines; D008996:Monoamine Oxidase Inhibitors; C058000:mofegiline; D008995:Monoamine Oxidase